Stroke case study

Case study level Ma - Eating is not the only problem treatment of stroke and its complications in the older person... 

Chris Cairns and Nina Barnett Case study level 1 - It is important to be regular constipation and the older person 409 Case study level 2 - Puffing away makes you lose your puff treatment of chronic obstructive pulmonary disease 411 Case study level 3 - Not what you first thought multiple morbidity in older people - acute confusional state, dehydration and Parkinson s disease 412 Case study level Ma - Eating is not the only problem treatment of stroke and its complications in the older person 414 Case study level Mb - Hearts and bones 416... 

Ogata J, Yonemura K, Kimura K et al. (2005). Cerebral infarction associated with essential thrombocythemia an autopsy case study. Cerebrovascular Diseases 19 201-205 Olin JW, Shih A (2006). Thromboangiitis obliterans (Buerger s disease). Current Opinions in Rheumatology 18 18-24 Orencia AJ, Petty GW, Khandheria BK et al. (1995a). Risk of stroke with mitral valve prolapse in population-based cohort study. Stroke 26 7-13... 

Kaberi-Otarod J, Conetta R, Kundo KK, Farkash A. Ischemic stroke in a user of thermadrene a case study in alternative medicine. Clin Pharmacol Ther 2002 72(3) 343-6. 

In the only large study ever done to assess risk factors for stroke in young people (age 20-49) over a 1 -yr period (in Poland, a country where ephedra based products are widely used), nearly half the stroke cases were associated with preexisting hypertension, another 15% had hyperlipidemia, and 6% were diabetic (Jovanovic, 1996). None of the individuals were ephedrine users. 

Bennett, Andrew, and Alexander L. George. Case Studies and Process Tracing in History and Political Science Similar Strokes for Different Foci. In Colin Elman and Miriam Fendius Eknan, eds.. Bridges and Boundaries Historians, Political Scientists, and the Study of International Relations. Cambridge, MA MIT Press, 2001, pp. 137-66. 

Case Study 3 illustrates how several problems associated with a single step could be solved in one stroke simply by modifying the reaction conditions appropriately. The... 

Figure 2 shows case study for comparison with lEC 61511 and suggested SRS. The case study is carried out to compare specific requirements for the same SIF. Some requirements combine several similar requirements into one in the suggested SRS format. The requirements related to proof test and partial stroke test are added to the SRS, respectively. Therefore, the list of suggested requirements has simpler form than the conventional one. 

These studies raise the possibility that, one day, imaging-based treatment protocols may allow for intravenous thrombolysis in patients well outside of the now-accepted 3-hour window, provided they demonstrate substantial diffusion-perfusion mismatch. Such protocols could allow for treatment of a vastly larger number of patients than are currently treated. It has been estimated that only 1-7% of acute stroke patients currently receive thrombolytic medication, and that, in up to 95% of cases, they are ineligible because they present outside of the 3-hour time window. As many as 80% of patients who present 6 hours after stroke onset may demonstrate a significant diffusion-perfusion mismatch. "... 

The GP Ilb-IIIa complex inhibitor Tirofiban has been used as an adjunct to thrombolysis in a number of small case series reports." A small transcranial Doppler (TCD) study suggests that it reduces microembolization from unstable carotid plaque." In an open pilot smdy, Tirohban administered within 9 hours after stroke onset blocked the conversion of ischemic penumbra to mature infarction." A phase III study (SETIS) has started recruiting patients to investigate its efficacy versus aspirin within the 6-hour window. 

Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke A pilot case-referent study. Stroke 2001 32 1112-1115. 

The abciximab in Acute Ischemic Stroke trial was a randomized, placebo-controlled dose-escalation study to examine the safety of abciximab in acute stroke. It randomized 74 patients within 24 hours of stroke onset to receive one of four doses of abciximab (by bolus with or without additional infusion, 54 patients) or placebo (20 patients). The median baseline National Institute of Health Stroke Scale (NIHSS) score was 15. The rates of asymptomatic ICH were 19% in the intervention group compared to 5% in the placebo group p = 0.07). Most (9 of 11) of the asymptomatic ICH patients had more severe stroke (NIHSS >14). No cases of symptomatic ICH or major systemic bleeding occurred. There was a trend toward a lower rate of stroke recurrence (2% vs. 5%) and a higher rate of functional recovery at 3 months in the group treated with abciximab than with placebo. 

Carotenoids and cardiovascular diseases — Numerous epidemiological studies aimed to study the relationship of carotenoids and cardiovascular diseases (CVDs) including coronary accident risk and stroke. It appeared then that observational studies, namely prospective and case-control studies, pointed to a protective effect of carotenoids on myocardial infarct and stroke, but also on some atherosclerosis markers such as intima media thickness (IMT) of the common carotid artery (CCA) and atheromatous plaque formation. 

---